Moxifloxacin Ophthalmic Solution Solution/ Drops
NDC Package 68083-210-01
Package Information
Moxifloxacin Ophthalmic Solution (moxifloxacin ophthalmic) solution/ dropses is moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans groupAcinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae* Chlamydia trachomatis*Efficacy for this organism was studied in fewer than 10 infections. This formulation utilizes a solution/ drops delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-210 and is authorized under FDA application ANDA208778.
Identification & Billing
- RxCUI: 403818 - moxifloxacin HCl 0.5 % Ophthalmic Solution
- RxCUI: 403818 - moxifloxacin 5 MG/ML Ophthalmic Solution
- RxCUI: 403818 - moxifloxacin (as moxifloxacin HCl) 0.5 % Ophthalmic Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-210 - Moxifloxacin Ophthalmic Solution
- 68083-210-01 - 1 BOTTLE, PLASTIC in 1 CARTON / 3 mL in 1 BOTTLE, PLASTIC
- 68083-210 - Moxifloxacin Ophthalmic Solution
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-210-01 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 3 ml in 1 bottle, plastic of Moxifloxacin Ophthalmic Solution, a human prescription drug labeled by Gland Pharma Limited. This solution/ drops is formulated for ophthalmic use and contains moxifloxacin hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on March 30, 2020. The current certification is valid through December 31, 2026.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083021001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.